K-Stemcell’s Arthritis Cell Therapy Set For Phase III In Korea
This article was originally published in PharmAsia News
Executive Summary
In another positive sign for South Korea’s stem cell space, one of the government’s priorities in the biotech sector, K-Stemcell will begin late-stage clinical trials with JOINTSTEM, an autologus adipose-derived stem cell therapy for degenerative arthritis, with a goal of commercialization in 2018.
You may also be interested in...
New OA Cell Therapy On Horizon As JointStem Study Succeeds
A novel stem cell therapy for osteoarthritis developed by South Korean biotech Nature Cell is set to debut in the country this year, providing an alternative for advanced patients who have limited treatment options.
No Korea-Originated New Drugs Approved Domestically In 2023
Notable new drug approvals in South Korea last year included Pfizer’s Tukysa, Genentech’s Columvi and BeiGene’s Tevimbra, but the tally did not include any domestically-originated products. Alzheimer’s disease therapy lecanemab may be on the horizon this year.
AI Healthcare, Medical Devices Shine In Korea Q1 Financings
After the financing draught suffered by Korean bioventures in 2023, it now seems the VC market is poised for a recovery as investors shift attention again to the healthcare sector, with a spotlight on AI-based solutions and device firms.